Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome.
In a double-blind trial patients with Argentine haemorrhagic fever treated with immune plasma within 8 days of the onset of the disease had a much lower mortality than those given normal plasma. Some patients treated with immune plasma developed late neurological complications.
D001782:Blood Donors; D002526:Cerebellar Diseases / Q000209:etiology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006478:Hemorrhagic Fever, American / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D009461:Neurologic Manifestations; D012189:Retrospective Studies; D013997:Time Factors